Key Highlights
- Xeris Biopharma (NASDAQ:XERS) closed at USD 13.17 on the snapshot date, up 25.91% in the latest session, 21.94% over 1 week, 28.74% over 1 month, 77.25% over 3 months and 100.46% over 6 months.
- Third quarter Revenue rose 44% to USD 107.2 million from USD 74.4 million, with Recorlev sales up 93% to USD 71.5 million and Net Income at USD 11.3 million against USD 0.6 million.
- Management raised 2026 total revenue guidance to USD 395 million to USD 405 million and lifted its 2030 outlook to more than USD 1 billion from about USD 750 million.
- The price implies a Market Value near USD 2.41 billion (calculated), which places the stock in the Mid cap bucket of USD 2 billion to USD 10 billion after the jump.
What Moved Xeris Biopharma (21.94% in a Week)
The company released third quarter 2026 results at 7:00 a.m. ET on November 5, 2026, and the shares rose 25.91% in that session to USD 13.17 from a prior close of USD 10.46. Total revenue grew 44% to USD 107.2 million, with net product revenue of USD 106.3 million, up 43%. Recorlev contributed USD 71.5 million against USD 37.0 million a year earlier, Keveyis added USD 13.0 million, up 9%, while Gvoke slipped 14% to USD 21.7 million. Gross Margin widened to 88% from 85%, and adjusted EBITDA reached USD 30.75 million versus USD 17.4 million. Net income was USD 11.3 million, or USD 0.06 per share, compared with USD 0.6 million a year earlier.
Why a Stock Like This Re-Rates: Guidance and a Bigger Long-Term Target
The catalyst here is an Earnings beat on product sales paired with a guidance raise. Full year 2026 total revenue is now guided to USD 395 million to USD 405 million, and the nine month total of USD 282.5 million, up 37%, shows the run rate behind it. Management also lifted its 2030 revenue outlook to more than USD 1 billion from about USD 750 million, which changes the long-term earnings math investors apply. Balance Sheet changes helped: cash rose to USD 131.1 million from USD 111.0 million at year end, long-term Debt fell to USD 189.7 million from USD 220.3 million, and the 2028 convertible notes were retired on July 15, 2026, removing about USD 34 million of debt.
Valuation, Liquidity and Risks After a Large Run
Gains of 28.74% over 1 month, 77.25% over 3 months and 100.46% over 6 months mean the stock has roughly doubled since spring, and the snapshot shows no year to date figure. At 182,700,038 shares outstanding and a float near 176.33 million, the calculated market value is about USD 2.41 billion, up from USD 1.91 billion at the earlier USD 10.46 price. Revenue growth is concentrated in one product: Recorlev made up about 67% of third quarter product revenue (simple arithmetic), while Gvoke is shrinking. After a move this size a small number of trades can move the price, spreads can be wide, and the move may reverse. Average Volume and the 52-week range were not available.
Where Things Stand
Xeris Biopharma (NASDAQ:XERS) rose because a quarter that beat on Recorlev Demand came with higher 2026 and 2030 revenue targets, and the stock now sits among the best-performing mid cap names of the past week at a 21.94% weekly gain, with 1-month and 6-month gains of 28.74% and 100.46%. The crossing of the USD 2 billion threshold, by calculation, moved it out of the small cap range. This is context, not a forecast or advice.






Please wait processing your request...